Delving into the Latest Updates on Triamcinolone Acetonide Acetate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [1]

Target

GR

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases

Active Indication

Dermatitis, AtopicDermatitis, SeborrheicEczema+ [2]

Inactive Indication-

Originator Organization

Tianjin Jinyao Pharmaceutical Co., Ltd.

Active Organization

Tianjin Jinyao Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1981),

Dermatitis, AtopicDermatitis, SeborrheicEczema+ [2]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC26H33FO7

InChIKeyVOBDXTSTTMAKHK-VHDCPBDGSA-N

CAS Registry3870-07-3

AbstractBackground and Aims:Chronic perineal pain (CPP) is the anorectal and perineal pain without underlying organic disease. The prevalence of CPP is 6–18%. The etiology for CPP may be idiopathic, benign, or malignant. We compared radiofrequency thermocoagulation of ganglion Impar with block using a combination of local anaesthetic and steroid for management of chronic perineal pain, with respect to pain relief, patients’ self-reported belief about the efficacy of treatment, and side effects or complications, if any.Material and Methods:Forty patients attending the Pain Management Centre of either sex in the age group of 20–70 years with history, physical examination, and pain patterns consistent with chronic perineal pain, who had been investigated to rule out malignancy and failed to respond to 6 weeks of conservative treatment with a combination of analgesics, anti-inflammatory drugs, neuromodulators, and physiotherapy, were enrolled in the study. The patients were randomly divided into two groups of 20 each using a computer-generated randomization number table. Group-I (n = 20): Patients were administered ganglion Impar block using a drug mixture comprising of 8 ml of 0.25% bupivacaine plus 80 mg of triamcinolone acetate under fluoroscopic guidance. Group II (n = 20): Patients received conventional radiofrequency thermocoagulation of ganglion Impar at 80 degree Celsius for 90 seconds under fluoroscopic guidance. Outcome assessment was done after minimally invasive pain and spine intervention (MIPSI) with evaluation of pain using the Numeric Rating Scale (0–10), patients’ self-reported belief about the efficacy of treatment using Patient Global Impression of Change (PGI-C), and side effects or complications, if any.Results:The majority of the patients in our study were in the age group of 40–50 years, and 80% of the patients were females and weighed 60–70 kg. The majority of the patients in our study had history of trauma, which led to coccygodynia. There was statistically and clinically significant improvement in pain score after ganglion Impar block in both the groups at all time intervals during the study period (P < 0.05). Patients’ self-reported belief about efficacy as per PGI-C was clinically and statistically better in group II as compared to group I at all time intervals throughout the study period (P < 0.005). Four patients in group I required second ganglion Impar block during the 12 months study period. The most common side effect was temporary pain on injection.Conclusions:Both the techniques of MIPSI, that is, fluoroscope-guided ganglion Impar block using corticosteroid and local anaesthetic and radiofrequency thermocoagulation, are effective and provide good pain relief to the symptomatic patients. With respect to improvement in pain relief and patients’ self-reported belief about the efficacy of treatment and side effects or complications, fluoroscope-guided ganglion Impar radiofrequency thermocoagulation is better as compared to fluoroscope-guided ganglion Impar block using corticosteroids and local anesthetics.

01 Feb 2025·Indian Journal of Ophthalmology

Management of Graves’ upper eyelid retraction (GUER): A review

Review

Author: Singh, Pallavi ; Rootman, Dan ; Desai, Akruti ; Naik, Milind N.

Graves’ disease, a common autoimmune disorder, characteristically presents with upper eyelid retraction, causing significant functional and cosmetic concerns for affected individuals. The management of Graves’ upper eyelid retraction has evolved significantly over recent years, with various surgical and non-surgical interventions. An ideal procedure is predictable and easily repeatable. This review provides a comprehensive overview of the contemporary approaches to managing Graves’ upper eyelid retraction, encompassing both traditional and emerging techniques. It critically evaluates the surgical options for correcting Graves’ upper eyelid retraction to achieve the desired eyelid contour, eyelid crease, tarsal platform show, and brow fat span. Their comparative effectiveness is meticulously explored, offering clinicians valuable insights into treatment selection. Moreover, this review also underscores combined orbital decompression with levator recession. Additionally, advancements in non-invasive modalities, including botulinum toxin, triamcinolone acetate injections, and hyaluronic acid fillers are discussed in detail. This review aims to facilitate informed decision-making and improve the overall outcomes for individuals affected by Graves’ disease-associated upper eyelid retraction.

01 Feb 2025·Arthroscopy: The Journal of Arthroscopic & Related Surgery

Postoperative Corticosteroid Injection After Arthroscopic Rotator Cuff Repair in Patients With Stiffness Has Similar Clinical Outcome Compared With Repair Combined With Capsular Release: A Prospective Randomized Clinical Trial

Article

Author: Lee, Hyo-Jin ; Yoon, Eun-Ji ; Kim, Jong-Ik ; Lee, Jung-Woo ; Kim, Jong-Ho

PURPOSETo investigate whether 2 months of a postoperative intra-articular corticosteroid injection after arthroscopic rotator cuff repair (ARCR) in rotator cuff tear (RCT) patients with stiffness would improve the functional scores and range of motion of the operated shoulder without capsular release during ARCR.METHODSFrom March 2020 to September 2021, a total of 73 patients who had RCT with stiffness and were scheduled for ARCR were enrolled prospectively and randomly allocated into 2 groups. The patients who underwent ARCR with capsular release were allocated to group 1 (n = 37). The patients who underwent ARCR without capsular release and were injected with 1 mL triamcinolone acetate (40 mg/1 cc) into the glenohumeral joint 2 months after surgery were allocated to group 2 (n = 36). Functional scores and shoulder range of motion were evaluated before surgery; 3, 6, and 12 months after surgery; and at the last follow-up. Magnetic resonance imaging was performed at 12 months postoperatively.RESULTSThe mean follow-up period was 26.5 months. The functional and visual analog score (VAS) pain scores in both groups were significantly improved at the last follow-up (P < .001). The 3-month postoperative VAS pain score of group 2 was significantly lower than that of group 1 (group 1, 3.4 ± 1.5; group 2, 2.1 ± 1.0; P <.001). VAS pain scores at 6 months or 12 months or at the last follow-up and functional scores and ROM at 3, 6, or 12 months or at the last follow-up were not significantly different between the 2 groups (P > .05). The retear rate of repaired rotator cuff during follow-up was not significantly different between the 2 groups (P = .71).CONCLUSIONSCorticosteroid injection in the glenohumeral joint performed 2 months after ARCR in RCT patients with stiffness is as effective as capsular release during ARCR for improving the clinical outcome of the operated shoulder.LEVEL OF EVIDENCELevel I, prospective randomized clinical trial.

100 Deals associated with Triamcinolone Acetonide Acetate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Triamcinolone Acetonide Acetate	N07XX08	DB11644

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	China	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Dermatitis, Seborrheic	China	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Eczema	China	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Neurodermatitis	China	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Pruritus	China	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04182672 (CTgov)	Phase 2	Greater Trochanteric Pain Syndrome	22	FX006	pchzpayacw(insgjpfbmr) = xreygjwuql apngchftgc (zahytrjqhj, enfildnctb - qortldvzfn) View more	-	02 Jan 2024
NCT04160091 (CTgov)	Phase 2	Bursitis \| Osteoarthritis \| Shoulder arthritis	19	FX006 (FX006 32mg in Glenohumeral OA Population)	vaxylbfnxq(opthlknjkn) = ssxtuezygo nengdnyewx (jzfdawqqxm, rwysyzpagm - htsnmgpwna) View more	-	30 Nov 2021
				Normal saline (Normal Saline in Glenohumeral OA Population)	vaxylbfnxq(opthlknjkn) = mthllegljo nengdnyewx (jzfdawqqxm, ykhtnsfstv - nebrvxdiqg) View more
PEACHTREE (AAO2021)	Phase 3	Uveitic Macular Edema	-	Suprachoroidal injection of CLS-TA	fzzrfwgdka(bmpchzgiqf) = qwtvlvnalp qngxzwcgpk (xafojkyztg ) View more	-	13 Nov 2021
				Suprachoroidal CLS-TA	(gagxvjeikv) = bbzkaxirgw nkpmlrzxtf (purkcigbcu ) View more
NCT03203447 (TOPAZ, CTgov)	Phase 3	Retinal Vein Occlusion \| Macular Edema	325	suprachoroidal CLS-TA+Lucentis or Avastin (Active)	uxdfugbnon(kddzfagyzq) = byepahcwkq pzkywhtrsv (pixhusgqte, tmiuohyalj - grdzilgmww) View more	-	23 Apr 2021
				suprachoroidal sham+Lucentis or Avastin (Control)	uxdfugbnon(kddzfagyzq) = onmsvsmism pzkywhtrsv (pixhusgqte, lerosijspl - akzhwyptud) View more
NCT02980874 (SAPPHIRE, CTgov)	Phase 3	Retinal Vein Occlusion \| Macular Edema	460	IVT aflibercept+suprachoroidal CLS-TA (Active)	lhpbpqraev(wczkdogcbk) = kobluatdve zihifkmnzr (oyxetesndh, mpyqxhbnhi - rjxyxyjhud) View more	-	14 Apr 2021
				suprachoroidal sham+IVT aflibercept (Control)	lhpbpqraev(wczkdogcbk) = byhmhsejzz zihifkmnzr (oyxetesndh, khdtbmtuha - ikxaitkktd) View more
NCT04065074 (CTgov)	Phase 2	Osteoarthritis, Hip	16	FX006 32 mg	xnndaigvoi(zmdamiquvr) = ttrmyrgdmn rdszsvwplx (mfzqjuazlf, nvszkpbtjt - apfihmlzix) View more	-	01 Dec 2020
NCT03793010 (CTgov)	Phase 3	Osteoarthritis, Hip	70	FX006 (FX006)	jirhwpclcs(qolqzwibuw) = zrgvpwqyge kfguwoxjca (azhipvefif, qmldhjuidp - isoolzxkhi) View more	-	14 Sep 2020
				Normal saline (Normal Saline)	jirhwpclcs(qolqzwibuw) = qjgrjooafy kfguwoxjca (azhipvefif, uvcabanvmb - jmphrqiigz) View more
NCT03382262 (CTgov)	Phase 2	Osteoarthritis, Hip \| Shoulder arthritis	55	FX006 (FX006 32 mg Shoulder)	rgjjoedelh(nmqrckqsjx) = gtbuxdfndj ykbgrtinxv (ouzltnfhzs, tshbsbpgtz - brxtkdwxms) View more	-	09 Dec 2019
				TAcs (TAcs 40 mg Shoulder)	rgjjoedelh(nmqrckqsjx) = kujqdawtfu ykbgrtinxv (ouzltnfhzs, sbgnunupox - muclzsssfw) View more
NCT01487200 (CTgov)	Phase 2	Osteoarthritis, Knee	24	FX006 10 mg (FX006 10mg)	socgjusajy(yeznrzvymm) = smmqszppvf qdgtgpiino (dgogipmcsj, txaezedcax - cmiylxttgj) View more	-	06 Dec 2019
				FX006 40 mg (FX006 40mg)	socgjusajy(yeznrzvymm) = qzeahxawal qdgtgpiino (dgogipmcsj, oohbjsjhvd - slazkfoueo) View more
NCT03046446 (CTgov)	Phase 3	Osteoarthritis, Knee	208	FX006 32 mg	kwihwbtcjc(qwpycyfddl) = cepxnzyczj ommwljilgm (fposqbuqwh, ecoerkqtkh - kftinmivwr) View more	-	29 Oct 2019